Genentech, a member of Roche (RHHBY), announced that the New England Journal of Medicine has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza. The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza reduced the odds of untreated household members contracting the virus by 32%. For the key secondary endpoint of influenza virus transmission resulting in symptoms, Xofluza showed a clinically meaningful reduction although statistical significance was not reached. Xofluza was well tolerated, with no new safety signals identified.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Trump Trade: Auto makers exempt from some U.S. tariffs
- Roche seeking U.S. tariff relief in direct talks with White House, Reuters says
- Roche Holding AG: Mixed Q1’25 Results and Strategic U.S. Investments Justify Hold Rating
- Roche sees FY25 core EPS growing in high single digit range
- Roche reports Q1 group sales CHF 15.4B vs. CHF 14.4B last year